ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended																1 Months Ended	12 Months Ended		12 Months Ended				12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012 Onglyza Kombiglyze [Member]	Dec. 31, 2011 Onglyza Kombiglyze [Member]	Dec. 31, 2010 Onglyza Kombiglyze [Member]	Dec. 31, 2012 AstraZeneca [Member]	Dec. 31, 2011 AstraZeneca [Member]	Dec. 31, 2010 AstraZeneca [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Acquisition [Member]	Dec. 31, 2012 AstraZeneca [Member] Onglyza Kombiglyze [Member]	Dec. 31, 2011 AstraZeneca [Member] Onglyza Kombiglyze [Member]	Dec. 31, 2010 AstraZeneca [Member] Onglyza Kombiglyze [Member]	Dec. 31, 2010 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Feb. 28, 2013 AstraZeneca [Member] dapagliflozin [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 AstraZeneca [Member] dapagliflozin [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] dapagliflozin [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Onglyza, Kombiglyze and dapagliflozin [Member] Amortization Income Expense [Member]	Dec. 31, 2011 AstraZeneca [Member] Onglyza, Kombiglyze and dapagliflozin [Member] Amortization Income Expense [Member]	Dec. 31, 2010 AstraZeneca [Member] Onglyza, Kombiglyze and dapagliflozin [Member] Amortization Income Expense [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Related Products [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Related Products [Member] Amylin Acquisition [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]
Alliances and Collaborations Statement [Line Items]
Payment made by a collaboration partner to enter into a collabroation agreement																															$ 3,600
Portion of preliminary proceeds included in accrued expenses related to collaboration proceeds adjustments																																73
Payment made by a collaboration partner as part of a tax sharing agreement																															207
Weighted-average useful life - Property, plant and equipment																		15 years 0 months 0 days
Weighted-average useful life - Acquired intangible assets																		12 years 0 months 0 days
Payment to be made by a collaboration partner to establish equal governance rights in the collaboration																																	135
Total upfront, milestone and other licensing payments																							300				250
Potential additional development and regulatory milestone receipts																											150
Potential additional sales based milestone receipts																							300				390
Net sales	4,191	3,736	4,443	5,251	5,454	5,345	5,434	5,011	17,621	21,244	19,484	709	473	158					972	473	158
Profit sharing expense																			425	207	67
Commercialization expense reimbursements to/(from) collaboration partner																			(141)	(40)	(33)
Research and development reimbursements to/(from) collaboration partner															(18)	40	19
Cost of products sold									4,610	5,598	5,277																							126
Other (income)/expense									80	334	93																	38	38	28
Upfront, milestone and other licensing payments received																						50			80	120						3,547
Deferred income	$ 4,849				$ 1,203				$ 4,849	$ 1,203													$ 208	$ 230		$ 142	$ 206				$ 3,500	$ 3,423
The percentage of capital expenditures to be reimbursed by AstraZeneca																																	50.00%